Compounded vs Approved Products

How we label evidence

We use plain labels: approved medicine (regulator and use named), established, promising but limited, mixed, insufficient evidence, preclinical (cells or animals only), no good evidence of benefit, evidence of harm, and marketing claim.

Definitions

• FDA-approved drug: reviewed by the FDA, which judges whether benefits outweigh risks for the intended population. [1]
• Compounded drug: not FDA-approved. The FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed. [2]
• Generic drug: approved under a different section of the law and shown to be therapeutically equivalent to a brand. A compounded drug is not a generic. [2]

Compounding has a real role. The FDA gives examples such as a patient allergic to a dye in the approved product, or a person who cannot swallow a tablet and needs a liquid. [2] It says compounded drugs should only be used when a patient's medical needs cannot be met by an approved drug. [2]

Who compounds, and under what standards

The FDA describes compounding by licensed pharmacists in state-licensed pharmacies, by physicians, and by outsourcing facilities. [2] Standards differ: outsourcing facilities (section 503B) follow current good manufacturing practice and are inspected by the FDA on a risk basis, while drugs compounded under section 503A are not subject to those requirements, and state boards of pharmacy generally handle day-to-day oversight of those pharmacies. [2] Biologics cannot be compounded under those exemptions. [2] A buyer often cannot tell which kind of compounder made a product ordered online. [2]

Comparison table

Worked example: compounded GLP-1 products

The FDA says unapproved GLP-1 versions, including compounded semaglutide and tirzepatide, do not undergo FDA review. [4] It reports:

• dosing-error adverse events with compounded injectable semaglutide, some requiring hospitalization [4]
• semaglutide salt forms, which are different active ingredients from the approved drug, with no known lawful basis for compounding [4]
• fraudulent products with false labels, including pharmacies that do not exist [4]
• retatrutide and cagrilintide cannot be used in compounding under federal law [4]
• as of May 31, 2026, 990 adverse event reports for compounded semaglutide and more than 730 for compounded tirzepatide, with likely underreporting because some pharmacies need not report [4]

A report is not proof the drug caused the event. [4] Many reported events resembled those of approved versions. [4] More on compounded and unapproved GLP-1 products.

Other peptides

For compounding substances such as BPC-157, CJC-1295, ipamorelin and GHRP-2, the FDA's category 2 page lists possible immune-reaction risks and, for some, serious adverse events or no human exposure data. [5] That page reflects the agency's safety concerns. Whether a given compound may legally be compounded is a separate, changing question; see compounded medicines.

Claim check: "It is the same as the brand, just cheaper"

• What it says: the compounded product equals the approved one.
• What the FDA says: claiming a compounded drug is the same as an approved drug is a telehealth red flag. [4]
• Where it stops: a compounded product may be appropriate in some cases, but equivalence has not been reviewed.

No universal winner

Approved products have been reviewed; compounded ones fill specific gaps. Which suits a person is a question for their prescriber, not a website. See talking with a health professional.